Tilray | TRLY - Gross Profit On Sales

Stock Price
9.15
Daily Change
-0.12 -1.29%
Monthly
-14.00%
Yearly
894.57%
Q1 Forecast
9.24

Tilray reported $67.63M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Cronos Group USD 16.19M 34.52M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD 226M 583M Dec/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Organon & Co USD 854M 3M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 67.63M 15.62M Mar/2025
Viatris USD 1.15B 223.6M Dec/2025
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025